Search

Your search keyword '"William D. Hanley"' showing total 22 results

Search Constraints

Start Over You searched for: Author "William D. Hanley" Remove constraint Author: "William D. Hanley" Topic business.industry Remove constraint Topic: business.industry
22 results on '"William D. Hanley"'

Search Results

1. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection

2. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate

3. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

4. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

5. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

6. The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation

7. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

8. Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients

9. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment

10. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial

11. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions

12. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

13. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

14. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women

15. Effect of Raltegravir on the Pharmacokinetics of Methadone

16. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy

17. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors

18. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease

20. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

21. Effects of omeprazole on plasma levels of raltegravir

22. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors

Catalog

Books, media, physical & digital resources